Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Appropriate control of blood pressure (BP) in hypertensive patients still represents the major therapeutic goal in the treatment of hypertension. Despite the growing attention and wide range of antihypertensive agents available in the clinical scenario, the target of BP below the advised thresholds of 140/90 mmHg is, unfortunately, often unreached. For this reason, the search for new antihypertensive agents is still ongoing. Azilsartan medoxomil, a new angiotensin receptor blocker that has been recently introduced in the clinical arena, represents the eighth angiotensin receptor blocker currently available for BP control. The aim of this paper is to describe the efficacy and safety profile of this new compound, reviewing available data obtained from both pre-clinical and clinical studies.

Original publication




Journal article


Vasc Health Risk Manag

Publication Date





299 - 305


angiotensin receptor blocker, azilsartan medoxomil, hypertension, Angiotensin II Type 1 Receptor Blockers, Animals, Antihypertensive Agents, Benzimidazoles, Blood Pressure, Drug Interactions, Evidence-Based Medicine, Humans, Hypertension, Oxadiazoles, Renin-Angiotensin System, Risk Assessment, Treatment Outcome